Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Biogen Inc. (BIIB)

305.15   1.7 (0.56%) 11-25 13:00
Open: 304.35 Pre. Close: 303.45
High: 307.527 Low: 302.7
Volume: 470,764 Market Cap: 43,942(M)

Technical analysis

as of: 2022-11-25 1:55:31 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 359.19     One year: 419.53
Support: Support1: 279.34    Support2: 261.92
Resistance: Resistance1: 307.52    Resistance2: 359.19
Pivot: 295.72
Moving Average: MA(5): 303.96     MA(20): 292.1
MA(100): 238.47     MA(250): 223.87
MACD: MACD(12,26): 11     Signal(9): 11.2
Stochastic oscillator: %K(14,3): 93.1     %D(3): 92.2
RSI: RSI(14): 71
52-week: High: 307.52  Low: 187.16
Average Vol(K): 3-Month: 1,662 (K)  10-Days: 1,111 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BIIB ] has closed below upper band by 22.4%. Bollinger Bands are 4.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 307.85 - 309.4 309.4 - 310.68
Low: 298.51 - 300.16 300.16 - 301.51
Close: 301.04 - 303.62 303.62 - 305.73

Company Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 24 Nov 2022
Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report? - Yahoo Finance

Wed, 23 Nov 2022
BIIB or RGEN: Which Is the Better Value Stock Right Now? - Nasdaq

Wed, 23 Nov 2022
Noteworthy ETF Inflows: RSP, BIIB, NFLX, ABMD - Nasdaq

Mon, 21 Nov 2022
Notable Monday Option Activity: BIIB, LCID, MA - Nasdaq

Thu, 17 Nov 2022
Is Biogen (BIIB) a Great Value Stock Right Now? - Yahoo Finance

Mon, 14 Nov 2022
Notable Monday Option Activity: IFF, PM, BIIB - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 144 (M)
Shares Float 144 (M)
% Held by Insiders 0.6 (%)
% Held by Institutions 88.3 (%)
Shares Short 2,470 (K)
Shares Short P.Month 2,710 (K)

Stock Financials

EPS 19.62
EPS Est Next Qtl 5.78
EPS Est This Year 22.1
EPS Est Next Year 23.81
Book Value (p.s.) 88.72
Profit Margin (%) 27.6
Operating Margin (%) 28.5
Return on Assets (ttm) 7.5
Return on Equity (ttm) 20.2
Qtrly Rev. Growth -9.7
Gross Profit (p.s.) 61.59
Sales Per Share 71.94
EBITDA (p.s.) 24.23
Qtrly Earnings Growth 253.1
Operating Cash Flow 2,400 (M)
Levered Free Cash Flow 2,310 (M)

Stock Valuations

PE Ratio 15.55
PEG Ratio -4.2
Price to Book value 3.43
Price to Sales 4.24
Price to Cash Flow 18.3

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.